stockrowNeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- +72.1%
- Free cash flow
- −3,724.2%
- Total debt
- +10.9%
Quarter to September 2026, against a year earlier
Follow NEO
Alert me
NeoGenomics, Inc. (NEO) EV/FCF
As of 5 November 2026, NeoGenomics, Inc. (NEO) trades at a EV/FCF of −96.9×. Over the past ten years it has ranged from −2,894× (October 2017) to 1,017× (February 2020); the current reading is higher than 23% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −95.9× | — |
| FY2024 | −65.9× | — |
| FY2023 | −69.4× | — |
| FY2022 | −14.5× | — |
| FY2021 | −45.3× | — |
| FY2020 | −207× | — |
| FY2019 | 858× | 2,123.85% |
| FY2018 | 38.6× | (78.50%) |
| FY2017 | 179× | 230.04% |
| FY2016 | 54.4× | (56.30%) |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | −106× | — |
| Jun 2026 | −440× | — |
| Mar 2026 | −449× | — |
| Dec 2025 | −95.9× | — |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| ADPT Adaptive Biotechnologies Corporation compare | −494× |
| NEO NeoGenomics, Inc. | −96.9× |
| FRNM Freenome, Inc compare | −27.7× |
| WGS GeneDx Holdings Corp. compare | −25.0× |
| PSNL Personalis, Inc. compare | −14.1× |
| OPK OPKO Health, Inc. compare | −9.6× |
| VCYT Veracyte, Inc. compare | 9.0× |
| CDNA CareDx, Inc. compare | 64.7× |
| CSTL Castle Biosciences, Inc. compare | 198× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on NEO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement